US FDA approves expanded use of J&J's cancer cell therapy

FDA allowed the expanded use of Johnson and Johnson Legend Biotech's Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer.

The Johnson & Johnson logo.

Credit: Reuters Photo

The US Food and Drug Administration on Friday allowed the expanded use of Johnson and Johnson Legend Biotech's Carvykti cell therapy as an earlier treatment for patients with a type of blood cancer.

Deccan Herald is on WhatsApp Channels | Join now for Breaking News & Editor's Picks